The time to offer treatments for COVID-19
| Autor: | David Peng, Preet M. Chaudhary, Fred R. Sattler, Marc Rendell, Leland Shapiro, Mika Turkia, Raphael Thomadsen, Denise Brennan-Rieder, Daniel G. Arkfeld, Binh Ngo, Gilles Hayem, Joseph Varon, Pierre Kory, Michael P. Dubé, Oriol Mitjà, Vito M. Campese, Iraldo Bello Rivero, Antonio Lobo-Ferreira, Cristina Mussini, Eivind H Vinjevoll, Daniel O. Griffin, Nicolas Peschanski, Gino K. In, Paul E. Marik, April W. Armstrong, Glenn Ehresmann, David Sawcer, Maria Carmela Piccirillo, Vicente Soriano, Marco Confalonieri, Diana L. Hanna, Stephen Ditmore, Rajkumar Dasgupta, Jose Iglesias, Ivan F H Hung, Miroslaw Smogorewski, Neha Nanda |
|---|---|
| Přispěvatelé: | T Ngo, Binh, Marik, Paul, Kory, Pierre, Shapiro, Leland, Thomadsen, Raphael, Iglesias, Jose, Ditmore, Stephen, Rendell, Marc, Varon, Joseph, Dubé, Michael, Nanda, Neha, In, Gino, Arkfeld, Daniel, Chaudhary, Preet, M Campese, Vito, L Hanna, Diana, E Sawcer, David, Ehresmann, Glenn, Peng, David, Smogorewski, Miroslaw, Armstrong, April, Dasgupta, Rajkumar, Sattler, Fred, Brennan-Rieder, Denise, Mussini, Cristina, Mitja, Oriol, Soriano, Vicente, Peschanski, Nicola, Hayem, Gille, Confalonieri, Marco, Carmela Piccirillo, Maria, Lobo-Ferreira, Antonio, Bello Rivero, Iraldo, Turkia, Mika, H Vingevoll, Eivind, Griffin, Daniel, Fn Hung, Ivan |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Emergency Use Authorization Time Factors Synthetic anti spike protein antibodie remdesivir Disease Interferon-β-1 0302 clinical medicine Pandemic Ambulatory Care Scopus Pharmacology (medical) synthetic anti-spike protein antibodies Randomized Controlled Trials as Topic COVID-19 Convalescent plasma Favipiravir HCQ Interferon-λ Ivermectin Remdesivir SARS-Cov-2 Synthetic anti spike protein antibodies Antibodies Monoclonal General Medicine Hospitalization Vaccination covid-19 030220 oncology & carcinogenesis Perspective convalescent plasma Research Article medicine.medical_specialty WOS(2) COVID-19 Vaccines hcq favipiravir ivermectin 03 medical and health sciences Ambulatory care interferon-β medicine Humans interferon-λ Intensive care medicine interferon-λ COVID-19 Serotherapy Pharmacology interferon-β business.industry Public health Immunization Passive interferon-β-1 1 COVID-19 Drug Treatment 030104 developmental biology Observational study business |
| Zdroj: | Re-Unir. Archivo Institucional de la Universidad Internacional de La Rioja instname Expert Opinion on Investigational Drugs article-version (VoR) Version of Record r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol |
| ISSN: | 1354-3784 |
| DOI: | 10.1080/13543784.2021.1901883 |
| Popis: | Introduction: COVID-19 has several overlapping phases. Treatment has focused on the late stage of the disease in hospital. Yet, the continuation of the pandemic is by propagation of the disease in outpatients. The current public health strategy relies solely on vaccines to prevent disease. Areas Covered: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results with subject numbers of 100 or more on, and used a targeted search to find announcements of unpublished trial results. As of 2/15/2021, we found 111 publications reporting findings in human studies on 14 classes of agents, and on 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care, the rest all in hospitalized patients. Remdesivir and convalescent plasma have emergency use authorization for hospitalized patients in the U.S.A. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. Monoclonal antibodies are authorized for outpatients, but the supply is inadequate to treat all at time of diagnosis. Favipiravir, ivermectin, and interferons are approved in certain countries Expert Opinion: Worldwide vaccination is now underway. Vaccines and antibodies are highly antigen specific and new variants are appearing. There is a need for treatment of outpatients who contract the disease, in addition to mass immunization. We call on public health authorities to authorize treatments with known low risk and potential benefit for use in parallel with mass immunization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|